ewsba.se
Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS molecular glue targeting solid tumors. In patients with non-small cell lung cancer, the therapy achieved a 62% response rate in late-line settings, rising to 75% for those previously treated with platinum therapies. Results for pancreatic cancer were also significant, showing a 50% response rate at the highest recommended dose of 32 mg daily.
The monotherapy was generally well-tolerated, with most side effects remaining low-grade and no treatment-related discontinuations reported. Pharmacokinetic data showed a steady, dose-dependent increase in exposure, effectively reducing tumor DNA across all tested patients at active dose levels. Early findings also suggest ERAS-0015 can be safely combined with standard treatments like panitumumab for colorectal cancer.
Photo by National Cancer Institute on Unsplash
Following these results, the company has narrowed its timeline for disclosing additional expansion and combination cohort data to H1 2027. Monotherapy expansion and combination trials are already underway in the US and China. These milestones support the company’s efforts to position ERAS-0015 as a backbone therapy for a variety of RAS-mutant cancers.
Erasca Inc. (NASDAQ:ERAS) is a California-based clinical-stage precision oncology company that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s core therapies include ERAS-0015, ERAS-4001, and ERAS-12.
While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.